OncoMark is focused on the development of novel panels of cancer biomarkers to aid treatment decisions and allow more tailored patient management, ultimately improving the quality of life for cancer patients.

read more »

Product

OncoMasTR is a novel prognostic assay for early stage breast cancer that is under development at OncoMark, and due for launch in July 2018. The biomarker assay will determine the risk of recurrence for early breast cancer patients. This assay will aid the clinicians in determining the best treatment options for their patients.  read more »

Prognostic multi-gene assay for early-stage breast cancer

Latest News

July 2017 - Cancer Research Publication

Irish-led research discovers potential new way to treat aggressive type of breast cancer

Study gives new hope of targeted treatment for triple negative breast cancer

Research led by Prof. William Gallagher, Director of BREAST-PREDICT and Chief Scientific Officer of OncoMark, has found a potential new approach to treating one of the most difficult-to-treat forms of breast cancer, which currently has limited treatment options.

May 2017 - Review published on MTRs

OncoMark Researchers Shed Light on the Discovery and Validation of Master Transcriptional Regulators in Cancer

OncoMark researchers have recently had a review published in the American Association for Cancer Research (AACR) journal, Cancer Research, describing how the reverse engineering of transcriptional networks using gene expression data enables the identification of genes that underpin the development and progression of different cancers.